GlassScriptPhysician profile
Toya Owens
NPI 1265049977
$6,098.10
in general payments reported to CMS, 2019-2025
22 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.62 · 2022: $414 · 2023: $919 · 2024: $2,253 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,608.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,277.78 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $715.73 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $660.13 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $534.39 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Axsome Therapeutics, INC. | $417.00 | 2024-2025 | Auvelity |
| Abbvie INC. | $376.78 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $304.08 | 2022-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $287.41 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $271.61 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $267.63 | 2021-2025 | Trintellix |
| Lundbeck LLC | $238.95 | 2022-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $200.88 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $135.17 | 2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Novo Nordisk INC | $124.56 | 2025 | Wegovy |
| Almatica Pharma LLC | $110.86 | 2024 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.39 | 2023 | Belsomra, Verquvo |
| Idorsia Pharmaceuticals US INC | $27.68 | 2024 | Quviviq |
| Corium, LLC | $27.66 | 2022-2025 | Azstarys |
| Biogen, INC. | $25.54 | 2024 | |
| Sunovion Pharmaceuticals INC. | $20.54 | 2022 | |
| Indivior INC. | $14.46 | 2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $13.87 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toya Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.